• S Brill, P M Sedgwick, W Hamann, and P P Di Vadi.
• Department of Anaesthetics and Pain Management, University Hospital Lewisham, Lewisham High Street, London SE13 6LH, UK.
• Br J Anaesth. 2002 Nov 1;89(5):711-4.

BackgroundPostherpetic neuralgia is a complication of acute herpes zoster characterized by severe pain and paraesthesia in the skin area affected by the initial infection. There is evidence that the N-methyl-D-aspartate receptor is involved in the development of hypersensitivity states and it is known that magnesium blocks the N-methyl-D-aspartate receptor.MethodA double-blind, placebo-controlled, cross-over study was conducted in which magnesium sulphate was administered as an i.v. infusion. Spontaneous pain was recorded and qualitative sensory testing with cotton wool was performed in seven patients with postherpetic neuralgia before and after the i.v. administration of either magnesium sulphate 30 mg kg(-1) or saline.ResultsDuring the administration, pain scores were significantly lower for magnesium compared with placebo at 20 and 30 min (P=0.016) but not at 10 min. I.V. magnesium sulphate was safe, well-tolerated and effective in patients with postherpetic neuralgia.ConclusionThe present study supports the concept that the N-methyl-D-aspartate receptor is involved in the control of postherpetic neuralgia.

This article appears in the collection: Magnesium the new 'roid.

23 keywords...

hide…